IVORC
  • Register
  • Login

Medical hypothesis, discovery & innovation in optometry

  1. Home
  2. Archives
  3. Vol. 3 No. 4 (2022): Winter 2022
  4. Articles

About the Journal

Editorial Team

Privacy Statement

Contact

Anterior-segment optical coherence tomography for tacrolimus therapy response monitoring of vernal keratoconjunctivitis

  • Mahmoud Eltagoury
  • Waleed Abou Samra
  • Ehab Ghoneim

Medical hypothesis, discovery & innovation in optometry, Vol. 3 No. 4 (2022), 14 January 2023 , Page 152-159
https://doi.org/10.51329/mehdioptometry164 Published 14 January 2023

  • View Article
  • Download
  • Share

Abstract

Background: Vernal keratoconjunctivitis (VKC), a chronic bilateral eye disease, is a severe form of allergic conjunctivitis. Anterior-segment optical coherence tomography (AS-OCT) is a rapid, noninvasive, in vivo visualization modality for the anterior segment structures that has been used in diagnosing and staging diseases and assessing the treatment efficacy. We used anterior-segment optical coherence tomography (AS-OCT) to monitor the efficacy of the tacrolimus eye ointment in managing VKC.
Methods: In this prospective follow-up study, we included patients with active symptomatic VKC. All patients were treated with the 0.03% tacrolimus ophthalmic ointment twice daily for 2 months and then once daily for 1 month. All patients underwent AS-OCT before and 3 months after treatment as an objective method to assess the treatment efficacy.
Results: We included 20 eyes of ten patients (nine men and one woman) with active symptomatic VKC. The mean age was 17.3 (range: 11 – 36) years, with nine patients having a palpebral type and one patient having a mixed type of VKC. Substantial flattening and reduction in the papilla size were observed in all patients at the post-treatment follow-up. AS-OCT measurements revealed significant reductions in the vertical, horizontal, and total diameters of the palpebral papillae and limbal conjunctival thickness after 3 months of treatment compared to baseline measurements (all P < 0.001). No serious adverse effects attributable to tacrolimus administration were observed in the study period.
Conclusions: AS-OCT is a suitable objective method for evaluating the treatment efficacy of the 0.03% tacrolimus eye ointment in patients with VKC. Future large-scale studies including a wide range of age groups with longer follow-up periods and AS-OCT monitoring at multiple post-treatment visits are required to confirm our preliminary results. Moreover, the diagnostic accuracy of AS-OCT in monitoring patients with active VKC should be tested in comparison with objective scoring by an experienced corneal fellowship.
Keywords:
  • tacrolimus anhydrous
  • vernal keratoconjunctivitis
  • optical coherence tomography
  • papillae
  • side effects
  • palpebral conjunctiva
  • bulbar conjunctiva
  • Full Text PDF
  • Abstract Viewed: 0 times
  • Full Text PDF Downloaded: 0 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram
Open Journal Systems
Make a Submission
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact

This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).
© Copyright 2020-2025, CC BY-NC 4.0. All Rights Reserved.

Medical Hypothesis, Discovery & Innovation in Optometry
ISSN 2693-8391